Global Biosimulation Market Research And Analysis, 2014-2020
MARKET INSIGHTS:
Global Biosimulation Market is expected to exceed $2.2 billion in 2020 with a CAGR 15.5% during 2015-2020. Rise in adoption of drug discovery and development and success in precision dosing are expected to boost global Biosimulation market. Biosimulation applications such as preclinical testing, clinical trials, target identification and validation, lead identification and optimization are widely adopted. These applications enable to provide faster and more certain results compared to conventional techniques as a result it is widely adopted across the globe. The technological advancement and innovation in Biosimulation products and applications enable to reduce the number of clinical studies for drug development. Model-based drug development reduce the clinical studies and offer better results. Biosimulation has huge contribution in personalized medicines which are adopted widely for better patient care. Due to the advancement in biosimulation the traditional one size fits all concept is replaced by personalized medicines. Biosimulation models enable to find better protection against various diseases such as tumor and other cancer cases through precise dozing. As a result it saves time, effort and money for drug development for many diseases.
Biosimulation technology offers virtual clinical trial population for pediatric, elderly and other group of patients. It enables to perform better clinical trials and reduce the time and effort for drug discovery and development. Technological advancement and innovation in biosimulation market enables to penetrate in emerging economies such as China, India, Japan and Korea. Biosimulation market by application such as preclinical testing, clinical trials, target identification and validation, lead identification and optimization are enhanced through research and development. Biosimulation market by product includes Pharmacokinetic/Pharmacodynamic (PK/PD), Molecular Modelling, Toxicity Prediction Software. These products enables to avoid drug-drug interaction studies, evaluating, genetic differences, predicting human doses and handling of drugs.
GEOGRAPHICAL INSIGHTS
North America generates highest revenues across the globe due to huge adoption of Biosimulation technology and highest rate of healthcare spending followed by Europe. Untapped APAC region such as China, India, Japan and Korea are the most emerging economies and expected to create huge opportunity for Biosimulation Market. Improved healthcare spending, infrastructure development and favorable government policies are the key factors which are expected to drive the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Strategic Recommendations, Key Company Analysis, GAP Analysis, Key Findings, Market Estimations, Market Insights, Analyst Insights and predictive analysis of the market. Global Biosimulation Market is expected to grow significantly due to rise in adoption of drug discovery and development, personalized medicine and success of precision dozing. The results of research & development and critical FDA approvals enable the Biosimulation Market to grow fast. Funding from government and private players are also key factors to drive the Global Biosimulation Market. However, high cost of Global Biosimulation products and application are concern for the growth of Biosimulation Market. The report also covers parametric analysis, historical analysis and Pipeline Analysis.
COMPETITIVE INSIGHTS:
The key players of Global Biosimulation Market includes Certara Us, Inc., Simulation Plus Inc., Dassault Systèmes SA, Schrodinger Inc., Advanced Chemistry Development, Inc., Chemical Computing Group, Inc., Entelos Holding Corporation, Genedata Ag, Physiomics PLC, Rhenovia Pharma Ltd, Accelrys Inc., Leadscope, Insilico Biosciences, Compugen, Nimbus Healthcare, Insilico Biosciences Inc., Inhibox, Johnson & Johnson, Biovia, Leadinvent Technologies and so on.
MARKET SEGMENTATION:
Global Biosimulation Market is segmented on the basis of application, product, end user and region. Global Biosimulation Market by application and end user has significant contribution in generating huge revenues across the globe. The Global Biosimulation Market by product such as PK/PD modelling and simulation, molecular modelling are widely adopted across the globe. Global simulation market by application such as drug development, preclinical testing, drug discovery and so on.
Global Biosimulation Market is expected to exceed $2.2 billion in 2020 with a CAGR 15.5% during 2015-2020. Rise in adoption of drug discovery and development and success in precision dosing are expected to boost global Biosimulation market. Biosimulation applications such as preclinical testing, clinical trials, target identification and validation, lead identification and optimization are widely adopted. These applications enable to provide faster and more certain results compared to conventional techniques as a result it is widely adopted across the globe. The technological advancement and innovation in Biosimulation products and applications enable to reduce the number of clinical studies for drug development. Model-based drug development reduce the clinical studies and offer better results. Biosimulation has huge contribution in personalized medicines which are adopted widely for better patient care. Due to the advancement in biosimulation the traditional one size fits all concept is replaced by personalized medicines. Biosimulation models enable to find better protection against various diseases such as tumor and other cancer cases through precise dozing. As a result it saves time, effort and money for drug development for many diseases.
Biosimulation technology offers virtual clinical trial population for pediatric, elderly and other group of patients. It enables to perform better clinical trials and reduce the time and effort for drug discovery and development. Technological advancement and innovation in biosimulation market enables to penetrate in emerging economies such as China, India, Japan and Korea. Biosimulation market by application such as preclinical testing, clinical trials, target identification and validation, lead identification and optimization are enhanced through research and development. Biosimulation market by product includes Pharmacokinetic/Pharmacodynamic (PK/PD), Molecular Modelling, Toxicity Prediction Software. These products enables to avoid drug-drug interaction studies, evaluating, genetic differences, predicting human doses and handling of drugs.
GEOGRAPHICAL INSIGHTS
North America generates highest revenues across the globe due to huge adoption of Biosimulation technology and highest rate of healthcare spending followed by Europe. Untapped APAC region such as China, India, Japan and Korea are the most emerging economies and expected to create huge opportunity for Biosimulation Market. Improved healthcare spending, infrastructure development and favorable government policies are the key factors which are expected to drive the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Strategic Recommendations, Key Company Analysis, GAP Analysis, Key Findings, Market Estimations, Market Insights, Analyst Insights and predictive analysis of the market. Global Biosimulation Market is expected to grow significantly due to rise in adoption of drug discovery and development, personalized medicine and success of precision dozing. The results of research & development and critical FDA approvals enable the Biosimulation Market to grow fast. Funding from government and private players are also key factors to drive the Global Biosimulation Market. However, high cost of Global Biosimulation products and application are concern for the growth of Biosimulation Market. The report also covers parametric analysis, historical analysis and Pipeline Analysis.
COMPETITIVE INSIGHTS:
The key players of Global Biosimulation Market includes Certara Us, Inc., Simulation Plus Inc., Dassault Systèmes SA, Schrodinger Inc., Advanced Chemistry Development, Inc., Chemical Computing Group, Inc., Entelos Holding Corporation, Genedata Ag, Physiomics PLC, Rhenovia Pharma Ltd, Accelrys Inc., Leadscope, Insilico Biosciences, Compugen, Nimbus Healthcare, Insilico Biosciences Inc., Inhibox, Johnson & Johnson, Biovia, Leadinvent Technologies and so on.
MARKET SEGMENTATION:
Global Biosimulation Market is segmented on the basis of application, product, end user and region. Global Biosimulation Market by application and end user has significant contribution in generating huge revenues across the globe. The Global Biosimulation Market by product such as PK/PD modelling and simulation, molecular modelling are widely adopted across the globe. Global simulation market by application such as drug development, preclinical testing, drug discovery and so on.
REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. CURRENT MARKET TRENDS
2.5. PIPELINE ANALYSIS
2.6. ANALYST INSIGHT
2.6.1. KEY FINDINGS
2.6.2. RECOMMENDATION
2.6.3. CONCLUSION
2.7. REGULATION
2.7.1. REGULATIONS ON CLINICAL TRIALS
2.7.1.1.1. UNITED STATES
2.7.1.1.2. EUROPEAN UNION
2.7.1.1.3. CHINA
2.7.1.1.4. INDIA
2.7.1.1.5. REST OF THE WORLD
2.7.1.2. DRUG AND DEVICE REGULATIONS
2.7.1.2.1. UNITED STATES
2.7.1.2.2. EUROPEAN UNION
2.7.1.2.3. CHINA
2.7.1.2.4. INDIA
2.7.1.2.5. REST OF THE WORLD
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. GLOBAL RISE IN ADOPTION OF DRUG DISCOVERY AND DEVELOPMENT
3.1.2. ENABLE TO REDUCE COST, AVOID ANIMAL EXPERIMENTATION AND COMPLEXITY OF TRADITIONAL SYSTEM
3.1.3. GLOBAL RISE IN THE ADOPTION OF PERSONALIZED MEDICINES ARE EXPECTED TO BOOST THE GLOBAL BIOSIMULATION MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENT AND INNOVATION IN GLOBAL BIOSIMULATION MARKET
3.1.5. FAVOURABLE GOVERNMENT POLICIES AND REGULATIONS
3.1.6. SUCCESS OF PRECISION DOSING
3.1.7. GLOBAL RISE IN HEALTHCARE EXPENDITURE ALSO FAVOURABLE FOR GLOBAL BIOSIMULATION MARKET
3.1.8. RESEARCH & DEVELOPMENT TO DRIVE THE BIOSIMULATION MARKET
3.2. RESTRAINT
3.2.1. HIGH COST OF BIOSIMULATION IS A CONCERN FOR THE MARKET
3.2.2. CHANCES OF ERROR IN BIOSIMULATION MODEL DEVELOPMENT APPROACHES
3.2.3. SOFTWARE FOR LARGE SCALE BIOSIMULATION MAY CREATE PROBLEM AND COMPLEXITY
3.3. OPPORTUNITY
3.3.1. SAVES COST AND REDUCE THE CLINICAL TRIAL DURATION
3.3.2. GLOBAL RISE IN PHARMACEUTICAL MARKET IS EXPECTED TO BOOST THE GLOBAL BIOSIMULATION MARKET
3.3.3. R&D OUTCOMES OF DRUG DEVELOPMENT IN NEXT FEW YEARS ARE EXPECTED TO DRIVE THE GLOBAL BIOSIMULATION MARKET
3.3.4. DRUG DISCOVERY AND DEVELOPMENT ARE EXPECTED TO REDUCE DRUG PRICES AND COMPLEXITY IN FUTURE
3.3.5. ADOPTION OF IMPROVED PATIENT HEALTHCARE
3.3.6. CLINICAL TRIALS ARE PREDICTED TO INCREASE IN NEXT FEW YEARS
3.3.7. REDUCTION IN LATE STAGE ATTRITION
3.3.8. COLLABORATION AND PARTNERSHIP ARE EXPECTED TO BOOST GLOBAL BIOSIMULATION MARKET
PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2014-2020,($ MILLIONS)
5.1.1. GLOBAL DRUG DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
5.1.1.1. GLOBAL PRECLINICAL TESTING MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
5.1.1.2. GLOBAL PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
5.1.1.3. GLOBAL ADME/TOX MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
5.1.1.4. GLOBAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
5.1.2. GLOBAL DRUG DISCOVERY MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.2.1. GLOBAL TARGET IDENTIFICATION AND VALIDATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.2.2. GLOBAL LEAD IDENTIFICATION AND OPTIMIZATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.3. GLOBAL OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2. GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY PRODUCT 2014-2020, ($ MILLIONS)
5.2.1. GLOBAL SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.1.1. GLOBAL PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELLING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.1.2. GLOBAL MOLECULAR MODELLING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.1.3. GLOBAL PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING (PBPK) MODELLING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.1.4. GLOBAL TOXICITY PREDICTION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.1.5. GLOBAL TRIAL DESIGN SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)RE
5.2.1.6. GLOBAL OTHER SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2. GLOBAL SERVICE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.3. GLOBAL EXTERNAL/CONTRACT SERVICES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3. GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY END USER 2014-2020, ($ MILLIONS)
5.4. GLOBAL BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.5. GLOBAL DRUG DISCOVERY AND DRUG DEVELOPMENT COMPANIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.6. GLOBAL EDUCATION CENTRES AND RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.7. GLOBAL REGULATORY AUTHORITIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.8. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
COMPETITIVE LANDSCAPE
6.1. MARKET SHARE ANALYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. CERTARA US, INC.
8.1.1. INTRODUCTION
8.1.2. CERTARA PRODUCT PORTFOLIO
8.1.3. CERTARA RECENT ACTIVITIES
8.1.4. CERTARA SWOT ANALYSIS
8.2. SIMULATION PLUS INC
8.2.1. INTRODUCTION
8.2.2. SIMULATION PLUS INC PRODUCT PORTFOLIO
8.2.3. SIMULATION PLUS INC RECENT ACTIVITIES
8.2.4. SIMULATION PLUS INC SWOT ANALYSIS
8.3. DASSAULT SYSTÈMES SA
8.3.1. INTRODUCTION
8.3.2. DASSAULT SYSTEMS SA PRODUCT PORTFOLIO
8.3.3. DASSAULT SYSTEMS SA RECENT ACTIVITIES
8.3.4. DASSAULT SYSTEMS SA SWOT ANALYSIS
8.4. SCHRÖDINGER INC.
8.4.1. INTRODUCTIONSS
8.4.2. SCHRODINGER INC PRODUCT PORTFOLIO
8.4.3. SCHRODINGER INC RECENT ACTIVITIES
8.4.4. SCHRODINGER INC SWOT ANALYSIS
8.5. ADVANCED CHEMISTRY DEVELOPMENT, INC.
8.5.1. INTRODUCTION
8.5.2. ADVANCED CHEMISTRY DEVELOPMENT PRODUCT PORTFOLIO
8.5.3. ADVANCED CHEMISTRY DEVELOPMENT RECENT ACTIVITIES
8.5.4. ADVANCED CHEMISTRY DEVELOPMENT SWOT ANALYSIS
8.6. CHEMICAL COMPUTING GROUP, INC.
8.6.1. INTRODUCTION
8.6.2. CHEMICAL COMPUTING GROUP, INC PRODUCT PORTFOLIO
8.6.3. CHEMICAL COMPUTING GROUP, INC RECENT ACTIVITIES
8.6.4. CHEMICAL COMPUTING GROUP, INC SWOT ANALYSIS
8.7. ENTELOS HOLDING CORPORATION
8.7.1. INTRODUCTION
8.7.2. ENTELOS HOLDING CORPORATION PRODUCT PORTFOLIO
8.7.3. ENTELOS HOLDING CORPORATION RECENT ACTIVITIES
8.7.4. ENTELOS HOLDING CORPORATION SWOT ANALYSIS
8.8. GENEDATA AG
8.8.1. INTRODUCTION
8.8.2. GENEDATA AG PRODUCT PORTFOLIO
8.8.3. GENEDATA AG RECENT ACTIVITIES
8.8.4. GENEDATA AG SWOT ANALYSIS
8.9. PHYSIOMICS PLC
8.9.1. INTRODUCTION
8.9.2. PHYSIOMICS PLC PRODUCT PORTFOLIO
8.9.3. PHYSIOMICS PLC RECENT ACTIVITIES
8.9.4. PHYSIOMICS PLC SWOT ANALYSIS
8.10. RHENOVIA PHARMA LTD
8.10.1. INTRODUCTION
8.10.2. RHENOVIA PRODUCT PORTFOLIO
8.10.3. RHENOVIA RECENT ACTIVITIES
8.10.4. RHENOVIA SWOT ANALYSIS
8.11. ACCELRYS INC.
8.11.1. INTRODUCTION
8.11.2. ACCELRYS INC PRODUCT PORTFOLIO
8.11.3. ACCELRYS INC RECENT ACTIVITIES
8.11.4. ACCELRYS INC SWOT ANALYSIS
8.12. LEADSCOPE
8.12.1. INTRODUCTION
8.12.2. LEADSCOPE PRODUCT PORTFOLIO
8.12.3. LEADSCOPE RECENT ACTIVITIES
8.12.4. LEADSCOPE SWOT ANALYSIS
8.13. INSILICO BIOSCIENCES
8.13.1. INTRODUCTION
8.13.2. INSILICO BIOSCIENCES PRODUCT PORTFOLIO
8.13.3. INSILICO BIOSCIENCES RECENT ACTIVITIES
8.13.4. INSILICO BIOSCIENCES SWOT ANALYSIS
8.14. COMPUGEN
8.14.1. INTRODUCTION
8.14.2. COMPUGEN PRODUCT PORTFOLIO
8.14.3. COMPUGEN RECENT ACTIVITIES
8.14.4. COMPUGEN SWOT ANALYSIS
8.15. NIMBUS HEALTHCARE
8.15.1. INTRODUCTION
8.15.2. NIMBUS PRODUCT PORTFOLIO
8.15.3. NIMBUS RECENT ACTIVITIES
8.15.4. NIMBUS SWOT ANALYSIS
8.16. INSILICO BIOSCIENCES INC
8.16.1. INTRODUCTION
8.16.2. INSILICO BIOSCIENCES INC PRODUCT PORTFOLIO
8.16.3. INSILICO BIOSCIENCES INC RECENT ACTIVITIES
8.16.4. INSILICO BIOSCIENCES INC SWOT ANALYSIS
8.17. INHIBOX
8.17.1. INTRODUCTION
8.17.2. INHIBOX PRODUCT PORTFOLIO
8.17.3. INHIBOX RECENT ACTIVITIES
8.17.4. INHIBOX SWOT ANALYSIS
8.18. JOHNSON & JOHNSON
8.18.1. INTRODUCTION
8.18.2. JOHNSON & JOHNSON PRODUCT PORTFOLIO
8.18.3. JOHNSON & JOHNSON RECENT ACTIVITIES
8.18.4. JOHNSON & JOHNSON SWOT ANALYSIS
8.19. BIOVIA
8.19.1. INTRODUCTION
8.19.2. BIOVIA PRODUCT PORTFOLIO
8.19.3. BIOVIA RECENT ACTIVITIES
8.19.4. BIOVIA DIAGNOSTIC SWOT ANALYSIS
8.20. LEADINVENT TECHNOLOGIES
8.20.1. INTRODUCTION
8.20.2. LEADINVENT TECHNOLOGIES PRODUCT PORTFOLIO
8.20.3. LEADINVENT TECHNOLOGIES RECENT ACTIVITIES
8.20.4. LEADINVENT TECHNOLOGIES SWOT ANALYSIS
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. CURRENT MARKET TRENDS
2.5. PIPELINE ANALYSIS
2.6. ANALYST INSIGHT
2.6.1. KEY FINDINGS
2.6.2. RECOMMENDATION
2.6.3. CONCLUSION
2.7. REGULATION
2.7.1. REGULATIONS ON CLINICAL TRIALS
2.7.1.1.1. UNITED STATES
2.7.1.1.2. EUROPEAN UNION
2.7.1.1.3. CHINA
2.7.1.1.4. INDIA
2.7.1.1.5. REST OF THE WORLD
2.7.1.2. DRUG AND DEVICE REGULATIONS
2.7.1.2.1. UNITED STATES
2.7.1.2.2. EUROPEAN UNION
2.7.1.2.3. CHINA
2.7.1.2.4. INDIA
2.7.1.2.5. REST OF THE WORLD
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. GLOBAL RISE IN ADOPTION OF DRUG DISCOVERY AND DEVELOPMENT
3.1.2. ENABLE TO REDUCE COST, AVOID ANIMAL EXPERIMENTATION AND COMPLEXITY OF TRADITIONAL SYSTEM
3.1.3. GLOBAL RISE IN THE ADOPTION OF PERSONALIZED MEDICINES ARE EXPECTED TO BOOST THE GLOBAL BIOSIMULATION MARKET
3.1.4. TECHNOLOGICAL ADVANCEMENT AND INNOVATION IN GLOBAL BIOSIMULATION MARKET
3.1.5. FAVOURABLE GOVERNMENT POLICIES AND REGULATIONS
3.1.6. SUCCESS OF PRECISION DOSING
3.1.7. GLOBAL RISE IN HEALTHCARE EXPENDITURE ALSO FAVOURABLE FOR GLOBAL BIOSIMULATION MARKET
3.1.8. RESEARCH & DEVELOPMENT TO DRIVE THE BIOSIMULATION MARKET
3.2. RESTRAINT
3.2.1. HIGH COST OF BIOSIMULATION IS A CONCERN FOR THE MARKET
3.2.2. CHANCES OF ERROR IN BIOSIMULATION MODEL DEVELOPMENT APPROACHES
3.2.3. SOFTWARE FOR LARGE SCALE BIOSIMULATION MAY CREATE PROBLEM AND COMPLEXITY
3.3. OPPORTUNITY
3.3.1. SAVES COST AND REDUCE THE CLINICAL TRIAL DURATION
3.3.2. GLOBAL RISE IN PHARMACEUTICAL MARKET IS EXPECTED TO BOOST THE GLOBAL BIOSIMULATION MARKET
3.3.3. R&D OUTCOMES OF DRUG DEVELOPMENT IN NEXT FEW YEARS ARE EXPECTED TO DRIVE THE GLOBAL BIOSIMULATION MARKET
3.3.4. DRUG DISCOVERY AND DEVELOPMENT ARE EXPECTED TO REDUCE DRUG PRICES AND COMPLEXITY IN FUTURE
3.3.5. ADOPTION OF IMPROVED PATIENT HEALTHCARE
3.3.6. CLINICAL TRIALS ARE PREDICTED TO INCREASE IN NEXT FEW YEARS
3.3.7. REDUCTION IN LATE STAGE ATTRITION
3.3.8. COLLABORATION AND PARTNERSHIP ARE EXPECTED TO BOOST GLOBAL BIOSIMULATION MARKET
PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2014-2020,($ MILLIONS)
5.1.1. GLOBAL DRUG DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
5.1.1.1. GLOBAL PRECLINICAL TESTING MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
5.1.1.2. GLOBAL PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
5.1.1.3. GLOBAL ADME/TOX MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
5.1.1.4. GLOBAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
5.1.2. GLOBAL DRUG DISCOVERY MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.2.1. GLOBAL TARGET IDENTIFICATION AND VALIDATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.2.2. GLOBAL LEAD IDENTIFICATION AND OPTIMIZATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.3. GLOBAL OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2. GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY PRODUCT 2014-2020, ($ MILLIONS)
5.2.1. GLOBAL SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.1.1. GLOBAL PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELLING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.1.2. GLOBAL MOLECULAR MODELLING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.1.3. GLOBAL PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING (PBPK) MODELLING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.1.4. GLOBAL TOXICITY PREDICTION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.1.5. GLOBAL TRIAL DESIGN SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)RE
5.2.1.6. GLOBAL OTHER SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2. GLOBAL SERVICE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.3. GLOBAL EXTERNAL/CONTRACT SERVICES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3. GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY END USER 2014-2020, ($ MILLIONS)
5.4. GLOBAL BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.5. GLOBAL DRUG DISCOVERY AND DRUG DEVELOPMENT COMPANIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.6. GLOBAL EDUCATION CENTRES AND RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.7. GLOBAL REGULATORY AUTHORITIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.8. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
COMPETITIVE LANDSCAPE
6.1. MARKET SHARE ANALYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. CERTARA US, INC.
8.1.1. INTRODUCTION
8.1.2. CERTARA PRODUCT PORTFOLIO
8.1.3. CERTARA RECENT ACTIVITIES
8.1.4. CERTARA SWOT ANALYSIS
8.2. SIMULATION PLUS INC
8.2.1. INTRODUCTION
8.2.2. SIMULATION PLUS INC PRODUCT PORTFOLIO
8.2.3. SIMULATION PLUS INC RECENT ACTIVITIES
8.2.4. SIMULATION PLUS INC SWOT ANALYSIS
8.3. DASSAULT SYSTÈMES SA
8.3.1. INTRODUCTION
8.3.2. DASSAULT SYSTEMS SA PRODUCT PORTFOLIO
8.3.3. DASSAULT SYSTEMS SA RECENT ACTIVITIES
8.3.4. DASSAULT SYSTEMS SA SWOT ANALYSIS
8.4. SCHRÖDINGER INC.
8.4.1. INTRODUCTIONSS
8.4.2. SCHRODINGER INC PRODUCT PORTFOLIO
8.4.3. SCHRODINGER INC RECENT ACTIVITIES
8.4.4. SCHRODINGER INC SWOT ANALYSIS
8.5. ADVANCED CHEMISTRY DEVELOPMENT, INC.
8.5.1. INTRODUCTION
8.5.2. ADVANCED CHEMISTRY DEVELOPMENT PRODUCT PORTFOLIO
8.5.3. ADVANCED CHEMISTRY DEVELOPMENT RECENT ACTIVITIES
8.5.4. ADVANCED CHEMISTRY DEVELOPMENT SWOT ANALYSIS
8.6. CHEMICAL COMPUTING GROUP, INC.
8.6.1. INTRODUCTION
8.6.2. CHEMICAL COMPUTING GROUP, INC PRODUCT PORTFOLIO
8.6.3. CHEMICAL COMPUTING GROUP, INC RECENT ACTIVITIES
8.6.4. CHEMICAL COMPUTING GROUP, INC SWOT ANALYSIS
8.7. ENTELOS HOLDING CORPORATION
8.7.1. INTRODUCTION
8.7.2. ENTELOS HOLDING CORPORATION PRODUCT PORTFOLIO
8.7.3. ENTELOS HOLDING CORPORATION RECENT ACTIVITIES
8.7.4. ENTELOS HOLDING CORPORATION SWOT ANALYSIS
8.8. GENEDATA AG
8.8.1. INTRODUCTION
8.8.2. GENEDATA AG PRODUCT PORTFOLIO
8.8.3. GENEDATA AG RECENT ACTIVITIES
8.8.4. GENEDATA AG SWOT ANALYSIS
8.9. PHYSIOMICS PLC
8.9.1. INTRODUCTION
8.9.2. PHYSIOMICS PLC PRODUCT PORTFOLIO
8.9.3. PHYSIOMICS PLC RECENT ACTIVITIES
8.9.4. PHYSIOMICS PLC SWOT ANALYSIS
8.10. RHENOVIA PHARMA LTD
8.10.1. INTRODUCTION
8.10.2. RHENOVIA PRODUCT PORTFOLIO
8.10.3. RHENOVIA RECENT ACTIVITIES
8.10.4. RHENOVIA SWOT ANALYSIS
8.11. ACCELRYS INC.
8.11.1. INTRODUCTION
8.11.2. ACCELRYS INC PRODUCT PORTFOLIO
8.11.3. ACCELRYS INC RECENT ACTIVITIES
8.11.4. ACCELRYS INC SWOT ANALYSIS
8.12. LEADSCOPE
8.12.1. INTRODUCTION
8.12.2. LEADSCOPE PRODUCT PORTFOLIO
8.12.3. LEADSCOPE RECENT ACTIVITIES
8.12.4. LEADSCOPE SWOT ANALYSIS
8.13. INSILICO BIOSCIENCES
8.13.1. INTRODUCTION
8.13.2. INSILICO BIOSCIENCES PRODUCT PORTFOLIO
8.13.3. INSILICO BIOSCIENCES RECENT ACTIVITIES
8.13.4. INSILICO BIOSCIENCES SWOT ANALYSIS
8.14. COMPUGEN
8.14.1. INTRODUCTION
8.14.2. COMPUGEN PRODUCT PORTFOLIO
8.14.3. COMPUGEN RECENT ACTIVITIES
8.14.4. COMPUGEN SWOT ANALYSIS
8.15. NIMBUS HEALTHCARE
8.15.1. INTRODUCTION
8.15.2. NIMBUS PRODUCT PORTFOLIO
8.15.3. NIMBUS RECENT ACTIVITIES
8.15.4. NIMBUS SWOT ANALYSIS
8.16. INSILICO BIOSCIENCES INC
8.16.1. INTRODUCTION
8.16.2. INSILICO BIOSCIENCES INC PRODUCT PORTFOLIO
8.16.3. INSILICO BIOSCIENCES INC RECENT ACTIVITIES
8.16.4. INSILICO BIOSCIENCES INC SWOT ANALYSIS
8.17. INHIBOX
8.17.1. INTRODUCTION
8.17.2. INHIBOX PRODUCT PORTFOLIO
8.17.3. INHIBOX RECENT ACTIVITIES
8.17.4. INHIBOX SWOT ANALYSIS
8.18. JOHNSON & JOHNSON
8.18.1. INTRODUCTION
8.18.2. JOHNSON & JOHNSON PRODUCT PORTFOLIO
8.18.3. JOHNSON & JOHNSON RECENT ACTIVITIES
8.18.4. JOHNSON & JOHNSON SWOT ANALYSIS
8.19. BIOVIA
8.19.1. INTRODUCTION
8.19.2. BIOVIA PRODUCT PORTFOLIO
8.19.3. BIOVIA RECENT ACTIVITIES
8.19.4. BIOVIA DIAGNOSTIC SWOT ANALYSIS
8.20. LEADINVENT TECHNOLOGIES
8.20.1. INTRODUCTION
8.20.2. LEADINVENT TECHNOLOGIES PRODUCT PORTFOLIO
8.20.3. LEADINVENT TECHNOLOGIES RECENT ACTIVITIES
8.20.4. LEADINVENT TECHNOLOGIES SWOT ANALYSIS
LIST OF TABLES
TABLE # 1 GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2014-2020,($ MILLIONS)
TABLE # 2 GLOBAL DRUG DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
TABLE # 3 GLOBAL PRECLINICAL TESTING MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
TABLE # 4 GLOBAL PHARMACOKINETIC/PHARMACODYNAMICS (PK/PD) MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
TABLE # 5 GLOBAL ADME/TOX MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
TABLE # 6 GLOBAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
TABLE # 7 GLOBAL DRUG DISCOVERY MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 8 GLOBAL TARGET IDENTIFICATION AND VALIDATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 9 GLOBAL LEAD IDENTIFICATION AND OPTIMIZATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 10 GLOBAL OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 11 GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY PRODUCT 2014-2020, ($ MILLIONS)
TABLE # 12 GLOBAL SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 13 GLOBAL PHARMACOKINETIC/PHARMACODYNAMICS (PK/PD) MODELING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 14 GLOBAL MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 15 GLOBAL PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING (PBPK) MODELING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 16 GLOBAL TOXICITY PREDICTION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 17 GLOBAL TRIAL DESIGN SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)RE
TABLE # 18 GLOBAL OTHER SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 19 GLOBAL OTHER SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 20 GLOBAL SERVICE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 21 GLOBAL EXTERNAL/CONTRACT SERVICES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 22 GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY END USER 2014-2020, ($ MILLIONS)
TABLE # 23 GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 24 GLOBAL DRUG DEVELOPMENT AND DRUG DISCOVERY COMPANIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 25 GLOBAL RESEARCH INSTITUTES AND EDUCATION CENTRES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 26 GLOBAL REGULATORY AUTHORITIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 27 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 1 GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2014-2020,($ MILLIONS)
TABLE # 2 GLOBAL DRUG DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
TABLE # 3 GLOBAL PRECLINICAL TESTING MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
TABLE # 4 GLOBAL PHARMACOKINETIC/PHARMACODYNAMICS (PK/PD) MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
TABLE # 5 GLOBAL ADME/TOX MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
TABLE # 6 GLOBAL CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS, 2014-2020,($ MILLIONS)
TABLE # 7 GLOBAL DRUG DISCOVERY MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 8 GLOBAL TARGET IDENTIFICATION AND VALIDATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 9 GLOBAL LEAD IDENTIFICATION AND OPTIMIZATION MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 10 GLOBAL OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 11 GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY PRODUCT 2014-2020, ($ MILLIONS)
TABLE # 12 GLOBAL SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 13 GLOBAL PHARMACOKINETIC/PHARMACODYNAMICS (PK/PD) MODELING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 14 GLOBAL MOLECULAR MODELING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 15 GLOBAL PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING (PBPK) MODELING AND SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 16 GLOBAL TOXICITY PREDICTION SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 17 GLOBAL TRIAL DESIGN SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)RE
TABLE # 18 GLOBAL OTHER SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 19 GLOBAL OTHER SOFTWARE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 20 GLOBAL SERVICE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 21 GLOBAL EXTERNAL/CONTRACT SERVICES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 22 GLOBAL BIOSIMULATION MARKET RESEARCH AND ANALYSIS, BY END USER 2014-2020, ($ MILLIONS)
TABLE # 23 GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 24 GLOBAL DRUG DEVELOPMENT AND DRUG DISCOVERY COMPANIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 25 GLOBAL RESEARCH INSTITUTES AND EDUCATION CENTRES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 26 GLOBAL REGULATORY AUTHORITIES MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 27 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
LIST OF FIGURES
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANIES MENTIONED
1. CERTARA US, INC.
2. SIMULATION PLUS INC
3. DASSAULT SYSTÈMES SA
4. SCHRÖDINGER INC.
5. ADVANCED CHEMISTRY DEVELOPMENT, INC.
6. CHEMICAL COMPUTING GROUP, INC.
7. ENTELOS HOLDING CORPORATION
8. GENEDATA AG
9. PHYSIOMICS PLC
10. RHENOVIA PHARMA LTD
11. ACCELRYS INC.
12. LEADSCOPE
13. INSILICO BIOSCIENCES
14. COMPUGEN
15. NIMBUS HEALTHCARE
16. INSILICO BIOSCIENCES INC
17. INHIBOX
18. JOHNSON & JOHNSON
19. BIOVIA
20. LEADINVENT TECHNOLOGIES
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANIES MENTIONED
1. CERTARA US, INC.
2. SIMULATION PLUS INC
3. DASSAULT SYSTÈMES SA
4. SCHRÖDINGER INC.
5. ADVANCED CHEMISTRY DEVELOPMENT, INC.
6. CHEMICAL COMPUTING GROUP, INC.
7. ENTELOS HOLDING CORPORATION
8. GENEDATA AG
9. PHYSIOMICS PLC
10. RHENOVIA PHARMA LTD
11. ACCELRYS INC.
12. LEADSCOPE
13. INSILICO BIOSCIENCES
14. COMPUGEN
15. NIMBUS HEALTHCARE
16. INSILICO BIOSCIENCES INC
17. INHIBOX
18. JOHNSON & JOHNSON
19. BIOVIA
20. LEADINVENT TECHNOLOGIES
